Tüdőrák: nyitott vizsgálatok itt: Szingapúr
43 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Singapore
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422EU 2023-506327-29-00Regiszter frissítve: 2026-11-09
1/2. fázisToborozTrial-stage medicine
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Where
- Singapore
- Age
- 18 év and over
- People
- 340 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT04198766Regiszter frissítve: 2026-11-06
1/2. fázisToborozTrial-stage medicine
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Singapore
- Age
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626EU 2024-514266-39-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Singapore
- Age
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356EU 2022-501863-41-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- Singapore
- Age
- 18 év and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784EU 2024-518154-16-00Regiszter frissítve: 2026-11-06
1/2. fázisToborozTrial-stage medicine
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
- Where
- Singapore
- Age
- 18 év and over
- People
- 315 worldwide
- Run by
- Voronoi, Inc
See details and how to joinNCT07699328EU 2025-523122-40-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Singapore
- Age
- 18 év and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Singapore
- Age
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497EU 2025-523576-23-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Singapore
- Age
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277EU 2024-511319-91-00Regiszter frissítve: 2026-11-04
1/2. fázisToborozTrial-stage medicine
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Where
- Kent Ridge, Singapore
- Age
- 18 év and over
- People
- 675 worldwide
- Run by
- BlossomHill Therapeutics
See details and how to joinNCT06706076Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Singapore
- Age
- 18 év and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997Regiszter frissítve: 2026-11-02
3. fázisToborozTrial-stage medicine
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Singapore
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695EU 2025-521284-12-00Regiszter frissítve: 2026-11-02
2/3. fázisToborozTrial-stage medicine
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Singapore
- Age
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596EU 2023-508922-83-00Regiszter frissítve: 2026-10-30
1. fázisToborozTrial-stage medicine
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Singapore
- Age
- 18 év and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804EU 2024-511246-39-00Regiszter frissítve: 2026-10-28
1/2. fázisToborozTrial-stage medicine
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Singapore
- Age
- 18 év and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585EU 2024-515459-39-00Regiszter frissítve: 2026-10-28
1/2. fázisToborozTrial-stage medicine
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Where
- Singapore
- Age
- 18 év and over
- People
- 450 worldwide
- Run by
- Bayer
See details and how to joinNCT06914128EU 2025-520623-24-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Where
- Singapore
- Age
- 18 év and over
- People
- 390 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717EU 2024-519901-36-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Singapore
- Age
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517EU 2025-520565-51-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Singapore
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510EU 2025-523586-18-00Regiszter frissítve: 2026-10-23
2. fázisToborozTrial-stage medicine
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Singapore
- Age
- 18 év and over
- People
- 150 worldwide
- Run by
- AbbVie
See details and how to joinNCT06568939Regiszter frissítve: 2026-10-22
1/2. fázisToborozTrial-stage medicine
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Singapore
- Age
- 18 év and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172EU 2023-503795-24-00Regiszter frissítve: 2026-10-21
1/2. fázisToborozTrial-stage medicine
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
- Where
- Singapore
- Age
- 18 év and over
- People
- 80 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07564401Regiszter frissítve: 2026-10-19
2. fázisToborozTrial-stage medicine
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Singapore
- Age
- 18 év and over
- People
- 278 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07098338EU 2025-524843-11-00Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Singapore
- Age
- 18 év and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199EU 2025-521775-31-00Regiszter frissítve: 2026-10-13
2/3. fázisToborozTrial-stage medicine
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Singapore
- Age
- 18 év and over
- People
- 500 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080Regiszter frissítve: 2026-10-09
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.